MCL Literature Feed

Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

This case report describes mantle cell lymphoma presenting atypically as erosive duodenitis, highlighting a rare gastrointestinal manifestation that can mimic more common inflammatory conditions.

This case report identifies a rare, leukemic, cyclin D1/SOX11-negative MCL driven by a CCND3::IGH rearrangement, highlighting a diagnostic pitfall and the importance of molecular testing in atypical cases.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

This preclinical study identifies that the miR-17-92 cluster suppresses the tumor suppressor BTG2, leading to B-cell receptor signaling overactivation and suggesting BTG2 as a prognostic biomarker.

PLSCR1 induction by retinoic acid/interferon-α enhances immunogenic cell death in MCL, improving the efficacy of dendritic cell-based vaccines by boosting anti-tumor T-cell responses in vitro.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This case report describes a rare presentation of mantle cell lymphoma as a large right atrial mass, highlighting the potential for significant cardiac involvement and informing differential diagnosis.

Ibrutinib plus venetoclax shows high efficacy (83% CR) and deep MRD negativity with good tolerability in Japanese patients with relapsed/refractory MCL, supporting its use in this population.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This 2024 review of 80 FDA-approved kinase inhibitors highlights pirtobrutinib's recent approval for relapsed/refractory MCL, contextualizing its properties within the broader landscape of targeted therapies.

This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.

This preclinical study identifies the protease SENP3 as a novel driver of MCL proliferation via the Wnt10a signaling pathway, presenting SENP3 as a potential new therapeutic target.

Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.

This retrospective study of 134 patients demonstrates that adding a BTK inhibitor to chemotherapy improves efficacy and prolongs progression-free survival in relapsed/refractory MCL.

Preclinically, chlorambucil and ibrutinib show synergistic apoptosis in an MCL cell line, suggesting a novel chemo-BTKi combination strategy potentially mediated by inhibiting the AKT signaling pathway.

A novel BRAF N581S mutation was identified in mantle cell lymphoma, expanding the known genomic landscape and suggesting a potential new therapeutic target for this rare patient subset.

This case report documents the first complete response of frontline CNS-involved MCL to single-agent acalabrutinib, suggesting a potential chemotherapy-free, CNS-penetrant option for this high-risk population.

An MRD-driven, finite-duration venetoclax-lenalidomide-rituximab regimen is effective in relapsed/refractory MCL, even post-BTKi, allowing nearly half of patients to stop therapy and maintain durable molecular remissions.

The deubiquitinase USP35 stabilizes CXCR3 protein expression in MCL cells, promoting oncogenic signaling via JAK/STAT and c-Myc, identifying the USP35-CXCR3 axis as a novel therapeutic target.

This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.

This 15-year real-world study benchmarks MCL survival outcomes, reflecting evolving treatment eras and providing crucial prognostic data from routine clinical practice.

Upregulation of the mTOR pathway drives acquired resistance to PRMT5 inhibitors in preclinical MCL models; combining with an mTOR inhibitor like temsirolimus overcomes this resistance and improves survival.

Pirtobrutinib, a non-covalent BTKi, gained FDA accelerated approval for MCL after prior BTKi failure, offering a 50% overall response rate for this high-unmet-need population.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

Final overall survival data from a phase 2 trial confirm durable responses to acalabrutinib monotherapy in relapsed/refractory MCL, including in patients with poor prognostic features.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.